Expression level of immune checkpoint inhibitory factors in preeclampsia
Sahar Madadi(Tabriz University of Medical Sciences), Shadi Eghbal‐Fard(Tabriz University of Medical Sciences), Sina Mohammadinejad(Tabriz University of Medical Sciences), Roza Motavalli(Tabriz University of Medical Sciences), Sanam Dolati(Tabriz University of Medical Sciences), Jalal Etemadi(Tabriz University of Medical Sciences), Shahla Danaii(Academic Center for Education, Culture and Research), Amin Alizadegan(Tabriz University of Medical Sciences), Leili Aghebati‐Maleki(Tabriz University of Medical Sciences), Simin Taghavi(Tabriz University of Medical Sciences), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Hossein Samadi Kafil(Tabriz University of Medical Sciences), Mohammad Sadegh Soltani‐Zangbar(Tabriz University of Medical Sciences), Farhad Jadidi-Niaragh(Tabriz University of Medical Sciences)
Cited by 16
Related Papers
CAR T cells in solid tumors: challenges and opportunities
|Stem Cell Research & Therapy|2021|573
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
RETRACTED ARTICLE: A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine
|Journal of Translational Medicine|2021|204
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202